CHIASMA INC. COMPLETES $6.2M SERIES B ROUND

Chiasma Inc., a developer of an innovative platform technology for oral delivery of macromolecule drugs, has announced the completion of a $6.2 million Series B financing round. Chiasma intends to use these funds to advance its lead therapeutic candidates through clinical trials. The investment round was co-led by F-2 Ventures and the Ofer Hi-Tech Group, joined by the InnoMed Fund, which funded the entire Series A round, and by Yissum Ltd.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050912005540&newsLang=en)